Kobayashi H, Hayata T, Terao T, Kawashima Y
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine.
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Dec;41(12):1936-42.
The efficacy of two methods of chemotherapy in the treatment of patients with advanced ovarian cancer was compared on the basis of survival curves; one consisted of remission induction therapy alone with a combination of cisplatin (CDDP), adriamycin (ADM) and cyclophosphamide (CPM) (induction PAC therapy), and the other consisted of induction PAC therapy and additional maintenance therapy with cyclic PAC (cyclic PAC therapy). The subjects of the study were patients with advanced ovarian cancer in stages III and IV. Sixty-eight patients received induction PAC therapy alone and seventeen patients received both induction and cyclic PAC therapy. Demographic factors such as age at initial presentation, the stage of cancer (III or IV), surgical procedure, histological classification, number of courses of induction PAC, response rate, site of residual tumor after surgery and induction PAC therapy, and reduction rate of CA125 were compared in the two groups. When analyzed by the chi 2 test, none of these factors was significantly different in the two groups. Patients in the induction PAC therapy group received a median total dosage of CDDP 360 mg, ADM 235mg, and CPM 2.246mg. Patients in the cyclic PAC therapy group received CDDP 592mg, ADM 490mg, and CPM 4.642mg. Thus, the dosage of anticancer agents administered to the latter group was about twice as great as that administered to the former group. According to the Kaplan-Meier method, survival rates for the induction PAC therapy group were 88.2% for one year, 50.0% for two years, 28.0% for three years, and 8.8% for five years. The median survival period was 23 months.(ABSTRACT TRUNCATED AT 250 WORDS)
基于生存曲线比较了两种化疗方法治疗晚期卵巢癌患者的疗效；一种仅包括顺铂（CDDP）、阿霉素（ADM）和环磷酰胺（CPM）联合的缓解诱导疗法（诱导PAC疗法），另一种包括诱导PAC疗法及额外的周期性PAC维持疗法（周期性PAC疗法）。研究对象为Ⅲ期和Ⅳ期晚期卵巢癌患者。68例患者仅接受诱导PAC疗法，17例患者接受诱导和周期性PAC疗法。比较了两组患者的人口统计学因素，如初次就诊时的年龄、癌症分期（Ⅲ期或Ⅳ期）、手术方式、组织学分类、诱导PAC疗程数、缓解率、手术及诱导PAC治疗后残留肿瘤部位以及CA125降低率。经卡方检验分析，两组这些因素均无显著差异。诱导PAC疗法组患者接受的CDDP中位总剂量为360mg、ADM为235mg、CPM为2246mg。周期性PAC疗法组患者接受的CDDP为592mg、ADM为490mg、CPM为4642mg。因此，后一组给予的抗癌药物剂量约为前一组的两倍。根据Kaplan-Meier方法，诱导PAC疗法组的1年生存率为88.2%、2年生存率为50.0%、3年生存率为28.0%、5年生存率为8.8%。中位生存期为23个月。（摘要截选于250词）
